The MIST trial, sponsored by the NIDDK, aimed to evaluate the efficacy and safety of three treatment options for BPH, a prevalent condition affecting older males. The trial's termination due to recruitment challenges highlights potential market barriers for new BPH therapies. The competitive landscape includes established treatments and emerging minimally invasive options. Companies such as Urologix and Medtronic are key players in this space, indicating a need for innovative approaches to enhance patient recruitment and engagement in clinical trials. The findings could influence market strategies for existing and future BPH therapies.